| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider activity in GUTS over the last quarter tilts toward buying: insiders added a net 64,516 shares worth roughly $40K.
Classified under Biotechnology (Health Care sector), GUTS's insider flows are most useful compared with peers in the same group.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 540.6K | $394.7K | - | |
| Dir | 149.1K | $92.2K | - | |
| Dir | 40.9K | $34.8K | - | |
| Dir | 35.0K | $25.5K | - | |
| CFO | 20.0K | $13.7K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 6, 2024 | Cvf, LLC | 10% Owner | Buy | 333,333 | $15.00 | $4,999,995.00 | +7.7% | -39.0% | -84.2% |